Q2 2024 Earnings Estimate for Cardiol Therapeutics Inc. (NASDAQ:CRDL) Issued By Roth Capital

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Analysts at Roth Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.09) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.

Several other analysts also recently weighed in on CRDL. Canaccord Genuity Group lifted their target price on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Roth Mkm started coverage on shares of Cardiol Therapeutics in a research note on Wednesday. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research report on Friday, June 14th. Finally, Canaccord Genuity Group raised their target price on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.60.

Cardiol Therapeutics Price Performance

NASDAQ CRDL opened at $2.00 on Friday. The company has a 50-day moving average price of $2.20 and a two-hundred day moving average price of $1.64. Cardiol Therapeutics has a 52 week low of $0.66 and a 52 week high of $3.12. The stock has a market cap of $138 million, a price-to-earnings ratio of -5.71 and a beta of 0.99. The company has a current ratio of 2.81, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04).

Hedge Funds Weigh In On Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Tejara Capital Ltd increased its stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 29.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 645,457 shares of the company’s stock after purchasing an additional 148,396 shares during the quarter. Tejara Capital Ltd owned approximately 1.00% of Cardiol Therapeutics worth $578,000 as of its most recent filing with the Securities and Exchange Commission. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.